SK Biopharma announced on the 17th that its U.S.-based research subsidiary, SK Life Sciences Labs, has recruited Dr. Ryan Kruger as head of the biological institutional sector and Dr. Steven Knight as head of the chemical institutional sector.
Dr. Kruger is an expert in cancer biology and epigenetics, having led research and development at GlaxoSmithKline (GSK) and biotechnology corporations.
Dr. Knight worked at GSK for over 25 years, leading the development of new drug candidates based on small molecule compounds and targeted protein degradation (TPD).
SK Biopharma is researching radioactive pharmaceutical therapies (RPT) and TPD as next-generation modalities. The company noted it expects to expand its clinical-stage innovative anti-cancer portfolio by 2029 based on this recruitment.
SK Life Sciences, SK Biopharma's U.S. subsidiary, has appointed Dr. Evelyn See, a pediatric neurology expert, as the medical director (MD) of the central nervous system (CNS) clinical institutional sector, and Dr. Marcus Refler, an oncology expert, as the MD of the oncology and RPT clinical institutional sector.
SK Biopharma President Lee Dong-hoon said, “This recruitment of talent is one of the key strategies to significantly enhance SK Biopharma's global research and development competitiveness,” and he noted, “The hiring of world-class researchers will contribute to accelerating the development of innovative anti-cancer treatments and achieving the goal of becoming a leading global biotech.”